Internet Archive Scholar

THU0576 Cardiovascular risk in long-term juvenile idiopathic arthritis

I. Aranda-Valera, I. Arias de la Rosa, R. Roldan Molina, C. Ábalos-Aguilera, C. Pérez-Sánchez, A. Escudero, R. López-Pedrera, E. Collantes-Estévez, N. Barbarroja
2018 THURSDAY, 14 JUNE 2018   unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (67.2 kB)
https://web.archive.org/web/20190430155049/https://ard.bmj.com/content/annrheumdis/77/Suppl_2/489.2.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

Results: A total of 3975 courses of biologics with a total exposure of 7592 PY were identified with Etanercept (5376PY) followed by Adalimumab (1334PY), Tocilizumab (435PY), Abatacept (109PY), Infliximab (99PY), Anakinra (96 PY), Canakinumab (71PY) and Golimumab (67PY). Differences in JIA category distribution and concomitant treatment were noted. A total of 3586 AE (47.2/100PY), 461 (6.1) SAE and 629 (8.3) AESI were reported. The most common AESI were uveitis (194 (2.6)) followed by medically
more » ... mportant infections (155 (2.0)), cytopenias (62 (0.8)), hepatic events 39 (0.5), anaphylaxis (28 (0.4))), other autoimmunopathies (25 (0.3)), chronic inflammatory bowel disease (23 (0.3)), depression (17 (0.2)), macrophage activation syndrome (12 (0.2)), malignancies (8 (0.
doi:10.1136/annrheumdis-2018-eular.6254 fatcat:ogblrfoxa5bdtiojyzkpfxe454
Citation

I. Aranda-Valera, I. Arias de la Rosa, R. Roldan Molina, C. Ábalos-Aguilera, C. Pérez-Sánchez, A. Escudero, R. López-Pedrera, E. Collantes-Estévez, N. Barbarroja. "THU0576 Cardiovascular risk in long-term juvenile idiopathic arthritis." THURSDAY, 14 JUNE 2018 (2018)